

RealRate

PHARMACEUTICAL 2017

Intra-Cellular Therapies Inc. Rank 49 of 292









PHARMACEUTICAL 2017





Intra-Cellular Therapies Inc. Rank 49 of 292

The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 203% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	388,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,532
Liabilities, Non-Current	0
Other Assets	76
Other Compr. Net Income	273
Other Expenses	1,102
Other Liabilities	2,869
Other Net Income	-112,426
Other Revenues	331
Property and Equipment	628
Research and Development	93,832
Selling, General and Administrative Expense	24,758

Output Variable	Value in 1000 USD
Assets	388,903
Liabilities	13,401
Expenses	119,692
Revenues	331
Stockholders Equity	375,503
Net Income	-231,787
Comprehensive Net Income	-231,650
Economic Capital Ratio	206%

